CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE1

Conditions

Acute Lymphoblastic Leukemia · Recurrent Acute Lymphoblastic Leukemia · Recurrent B Acute Lymphoblastic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Contact: Study coordinator (Rebecca Epperly, MD) · referralinfo@stjude.org · 888-226-4343

Study leads

Rebecca Epperly, MD
Principal Investigator
St. Jude Children's Research Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL

Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE1

Taipei, Taiwan

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia · Non-Hodgkin Lymphoma of Soft Tissue

Abroad (travel likely)RecruitingEARLY_PHASE1

Hangzhou, China

Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Philadelphia Chromosome-Positive · Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

The Bronx, United States · Houston, United States

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

Acute Lymphoblastic Leukemia · Obesity

Abroad (travel likely)RecruitingPHASE2

Memphis, United States